On September 28, Twist Bioscience Corp rose 5.17% overnight to $192.29 per share, with turnover of $237,000, extending its recent strong momentum.

The move continues to be driven by the company's growing role as a key infrastructure provider in the AI drug discovery ecosystem. On September 16, Twist announced a collaboration with Lilly TuneLab, Eli Lilly's AI/ML drug discovery platform, to provide antibody characterization data services supporting AI-driven drugability prediction validation. Earlier in August, Twist was selected by Anthropic as an independent evaluator for a multi-arm AI protein design project, which triggered a 17% single-day surge. AI drug discovery-related orders have reportedly doubled from $25 million to $50 million, with projections reaching $100 million the following year.

Twist's silicon-based DNA synthesis platform positions it as a critical link in the design-build-test-learn loop for AI-driven drug development. However, the stock trades at an elevated valuation of approximately 22x price-to-sales, and insider filings disclosed on September 25 showed CEO Emily Leproust sold over 5,000 shares across multiple transactions on September 24.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)